不同炎性反应标志物预测慢性阻塞性肺疾病病情加重患者预后的比较

doi:10.3969/j.issn.1006-7795.2025.04.020

首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (4): 718-723.doi: 10.3969/j.issn.1006-7795.2025.04.020

不同炎性反应标志物预测慢性阻塞性肺疾病病情加重患者预后的比较

毛文苹,韩倩,焦风伟,王晶,黄克武^*

首都医科大学附属北京朝阳医院-北京市呼吸疾病研究所呼吸与危重症医学科，北京 100020

收稿日期:2025-01-17 出版日期:2025-08-21 发布日期:2025-09-01
通讯作者: 黄克武 E-mail:kewuhuang@126.com
基金资助:
北京市呼吸疾病研究所预算编制项目（Ysbz2025001）。

The predictive value of serum β2M level for prognosis in exacerbated COPD and the results of when it is compared with other inflammatory markers

Mao Wenping, Han Qian, Jiao Fengwei, Wang Jing, Huang Kewu^*

Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Received:2025-01-17 Online:2025-08-21 Published:2025-09-01
Supported by:
This study was supported by Financial Budgeting Project of Beijing Institute of Respiratory Medicine（Ysbz2025001）.

摘要/Abstract

摘要： 目的本研究主要探讨不同炎性反应标志物预测慢性阻塞性肺疾病（chronic obstructive pulmonary disease, COPD）病情加重住院患者短期预后的价值。方法纳入2012年12月31日至2017年12月28日因COPD病情加重为第一诊断于首都医科大学附属北京朝阳医院住院的患者，收集患者的临床资料，包含入院时测定的β2-微球蛋白（beta 2-microglobulin, β2M ）、中性粒细胞-淋巴细胞比值（neutrophils-lymphocytes ratio, NLR）、C-反应蛋白（C-reactive protein values, CRP）、白细胞计数（white blood cell, WBC）等相关资料，所有患者随访至90 d。采用Medcalc统计软件比较血清β2M与NLR、CRP、WBC对住院患者预后的预测价值。结果血清β2M、NLR、CRP对住院COPD病情加重患者30 d和90 d的病死有一定的预测价值，血清β2M预测患者30 d预后的受试者工作特征（receiver operating characteristic， ROC）曲线下面积均大于NLR和CRP，预测患者90 d预后的ROC曲线下面积大于CRP，略小于NLR。结论作为一个系统性生物标志物，血清β2M对住院COPD病情加重患者的短期病死有一定的预测价值，略优于CRP，不亚于NLR。

关键词: β2-微球蛋白, 慢性阻塞性肺疾病, 预后, C-反应蛋白, 中性粒细胞-淋巴细胞比值

Abstract: Objective To investigate the prognostic role of serum beta 2-microglobulin (β2M) as a systemic inflammatory biomarker in
hospitalized patients with exacerbation of COPD, compared with other inflammatory biomarkers. Methods We retrospectively analyzed hospitalized patients with exacerbated COPD as the first diagnosis at Beijing Chao-Yang hospital, P. R. China, from December 31, 2012 to December 28, 2017. Serum β2M levels, laboratory and clinical indexes were measured or collected on admission, and all patients were followed up for 90 days. The prognostic performance of β2M was compared with the neutrophils-lymphocytes ratio (NLR), C-reactive protein values (CRP) and white blood cell (WBC) using MedCalc. Results For 30-day mortality, β2M, NLR, and CRP showed significant predictive value (all P<0.001) and were better than WBC (P=0.044, 0.003 and 0.030, respectively) in hospitalized patients with exacerbated COPD , while WBC had no predictive significance. For 90-day mortality, β2M, NLR, CRP, and WBC were all statistically significant, but only NLR outperformed WBC (P=0.004). No significant differences were observed among β2M, NLR, and CRP. Conclusion As a systemic inflammatory biomarker, serum β2M was a useful prognostic biomarker for short-term death in hospitalized patients with COPD exacerbations. It performed slightly better than NLR and CRP for 30-day mortality prediction and slightly superior to CRP and slightly inferior to NLR for 90-day mortality prediction.

Key words: β2-microglobulin, COPD, prognosis, C-reactive protein, neutrophils-lymphocytes ratio

中图分类号:

毛文苹, 韩倩, 焦风伟, 王晶, 黄克武. 不同炎性反应标志物预测慢性阻塞性肺疾病病情加重患者预后的比较[J]. 首都医科大学学报, 2025, 46(4): 718-723.

Mao Wenping, Han Qian, Jiao Fengwei, Wang Jing, Huang Kewu. The predictive value of serum β2M level for prognosis in exacerbated COPD and the results of when it is compared with other inflammatory markers[J]. Journal of Capital Medical University, 2025, 46(4): 718-723.

参考文献

［1］Barnes P J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease［J］. J Allergy Clin Immunol, 2016, 138(1): 16－27.
［2］Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 report)［R］. (2021-11-15)［2022-05-05］. https://goldcopd.org/2022-gold-reports/.
［3］Wouters E F M, Creutzberg E C, Schols A M W J. Systemic effects in COPD［J］. Chest, 2002, 121(S5): 127S－130S.
［4］Celli B R, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease［J］. Am J Respir Crit Care Med, 2012, 185(10): 1065－1072.
［5］Eagan T M L, Ueland T, Wagner P D, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD cohort study［J］. Eur Respir J, 2010, 35(3): 540－548.
［6］Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis［J］. Eur Respir Rev, 2017, 26(143): 160070.
［7］Yao C Y, Liu X L, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD［J］. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2285－2290.
［8］Lu F Y, Chen R, Li N, et al. Neutrophil-to-lymphocyte ratio predicts clinical outcome of severe acute exacerbation of COPD in frequent exacerbators［J］. Int J Chron Obstruct Pulmon Dis, 2021, 16: 341－349.
［9］Paliogiannis P, Fois A G, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives［J］. Eur Respir Rev, 2018, 27(147): 170113.
［10］Mao W P, Wang J, Zhang L M, et al. Serum β2-Microglobulin is associated with mortality in hospitalized patients with exacerbated chronic obstructive pulmonary disease［J］. Int J Chron Obstruct Pulmon Dis, 2020, 15: 723－732.
［11］Mullerova H, Maselli D J, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort［J］. Chest, 2015, 147(4): 999－1007.
［12］Steer J, Gibson J, Bourke S C. The decaf score:predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease［J］. Thorax, 2012, 67(11): 970－976.
［13］Charlson M E, Pompei P, Ales K L, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation［J］. J Chronic Dis, 1987, 40(5): 373－383.
［14］Quan H, Li B, Couris C M, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries［J］. Am J Epidemiol, 2011, 173(6): 676－682.
［15］Chang C, Guo Z G, Shen N, et al. Dynamics of inflammation resolution and symptom recovery during AECOPD treatment［J］. Sci Rep, 2014, 4: 5516.
［16］Zijlstra M, Bix M, Simister N E, et al. Beta 2-microglobulin deficient mice lack CD4－8+ cytolytic T cells［J］. Nature, 1990, 344(6268): 742－746.
［17］Evrin P E, Wibell L. The serum levels and urinary excretion of 2-microglobulin in apparently healthy subjects［J］. Scand J Clin Lab Invest, 1972, 29(1): 69－74.
［18］Stanga Z, Nock S, Medina-Escobar P, et al. Factors other than the glomerular filtration rate that determine the serum beta－2-microglobulin level［J］. PLoS One, 2013, 8(8): e72073.
［19］Drüeke T B, Massy Z A. Beta2-microglobulin［J］. Semin dial, 2009, 22(4): 378－380.
［20］Miller J, Edwards L D, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort［J］. Respir Med, 2013, 107(9): 1376－1384.
［21］Barnes P J, Celli B R. Systemic manifestations and comorbidities of COPD［J］. Eur Respir J, 2009, 33(5): 1165－1185.
［22］Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD［J］. Eur Respir Rev, 2013, 22(130): 454－475.
［23］Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers［J］. Am J Respir Crit Care Med, 2011, 184(6): 662－671.
［24］Sproston N R, Ashworth J J. Role of C-reactive protein at sites of inflammation and infection［J］. Front Immunol, 2018, 9: 754.
［25］Fruchter O, Yigla M, Kramer M R. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation［J］. Am J Med Sci, 2015, 349(1): 29－35.
［26］Godtfredsen N S, Jørgensen D V, Marsaa K, et al. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD［J］. Respir Res, 2018, 19(1): 97.
［27］O'Donnell R, Breen D, Wilson S, et al. Inflammatory cells in the airways in COPD［J］. Thorax, 2006, 61(5): 448－454.
［28］Furutate R, Ishii T, Motegi T, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease［J］. Intern Med, 2016, 55(3): 223－229.
［29］Kurtipek E, Bekci T T, Kesli R, et al. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease［J］. J Pak Med Assoc, 2015, 65(12): 1283－1287.
［30］Rahimirad S, Ghaffary M R, Rahimirad M H, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease［J］. Tuberk Toraks, 2017, 65(1): 25－31.

[1]	郭宇, 陈伟观, 周三连, 汤莉巧, 孙王妍, 张冬梅, 卢红建. 急性缺血性脑卒中患者血清糖蛋白非转移性黑色素瘤蛋白B蛋白浓度与疾病严重度及预后的相关性分析[J]. 首都医科大学学报, 2025, 46(4): 702-709.
[2]	胡亚芬, 华琳. 肠道菌群与糖尿病、炎症因子及C反应蛋白的因果关系——孟德尔随机化分析[J]. 首都医科大学学报, 2024, 45(3): 488-493.
[3]	李琴, 胡悦, 秦啸峰, 冯志红, 王炜, 孙英. 呼吸道迟缓爱德华菌不同组分对肺部炎症作用的对比分析[J]. 首都医科大学学报, 2023, 44(6): 1036-1043.

不同炎性反应标志物预测慢性阻塞性肺疾病病情加重患者预后的比较

The predictive value of serum β2M level for prognosis in exacerbated COPD and the results of when it is compared with other inflammatory markers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价